Haemonetics (HAE) Tops Q3 EPS by 15c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $120.28 --0%
Revenue Growth %: +5.6%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +5.6%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q3 EPS of $0.81, $0.15 better than the analyst estimate of $0.66. Revenue for the quarter came in at $240 million versus the consensus estimate of $225.73 million.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- XPEL, Inc. (XPEL) Tops Q3 EPS by 4c, Misses on Revenue; Offers Q4 Revenue Guidance
- Peabody Energy (BTU) Misses Q3 EPS by 28c
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
